BioWorld - Friday, December 26, 2025 To read the full article sign up for free or sign in. Hightide’s HTD-1801 outperforms Farxiga in type 2 diabetes Dec. 2, 2025 By Tamra Sami Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met the primary endpoint showing superior improvements in key cardiometabolic markers in patients with type 2 diabetes compared to Astrazeneca plc’s SGLT2 inhibitor, Farxiga (dapagliflozin), in a head-to-head phase III trial. BioWorldBioWorld AsiaClinicalEndocrine/metabolicAsia-PacificChinaNMPA